Entrada Therapeutics, Inc. (TRDA) is a Biotechnology company in the Healthcare sector, currently trading at $14.03. It has a SharesGrow Score of 61/100, indicating a above average investment profile with 3 out of 7 criteria passed.
Analyst consensus target is TRDA = $18 (+28.3% upside).
Valuation: TRDA trades at a trailing Price-to-Earnings (P/E) of -4 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.43.
Financials: revenue is $25M, -12.3%/yr average growth. Net income is $144M (loss), growing at +285%/yr. Net profit margin is -565.5% (negative). Gross margin is 83.9% (+61.3 pp trend).
Balance sheet: total debt is $51M against $306M equity (Debt-to-Equity (D/E) ratio 0.17, conservative). Current ratio is 12.53 (strong liquidity). Debt-to-assets is 13.5%. Total assets: $377M.
Analyst outlook: 4 / 5 analysts rate TRDA as buy (80%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 92/100 (Pass), Growth 58/100 (Partial), Past 25/100 (Fail), Health 100/100 (Pass), Moat 56/100 (Partial), Future 88/100 (Pass), Income 10/100 (Fail).
